2010/06/07

TRIMETAZIDINE

International name:
Trimetazidine (Trimetazidine)

Group Affiliation:
Antigipoksantnoe tool

Description of the active substance (INN):
Trimetazidine

Dosage form:
coated tablets, tablets with prolonged action coated tablets with modified release coated tablets

Mode of action:
Has antianginalnoe, koronarodilatiruyuschee, antihypoxia and hypotensive action. Directly affecting cardiomyocytes and neurons of the brain, improves their metabolism and function. Cytoprotective effect explained by rising energy potential, activation of oxidative decarboxylase and rationalization of consumption of oxygen (increased aerobic glycolysis and the blockade of fatty acid oxidation). Supports myocardial contractility, prevents the depletion of intracellular ATP and fosfokreatinina. In acidosis, normalizes the function of ion channels of membranes, prevents the accumulation of Ca2 + and Na + in cardiomyocytes, normalizes intracellular concentration of K +. Reduces intracellular acidosis and phosphate concentrations resulting from myocardial ischemia and reperfusion. It prevents the damaging action of free radicals, preserves the integrity of cell membranes and prevents the activation of neutrophils in the ischemic area, increases the duration of the electric potential, reduces the yield of CK from the cells and the severity of ischemic myocardial injury. When reducing the frequency of attacks of angina (reduced consumption of nitrates), after 2 weeks of treatment increases exercise tolerance, reduced blood pressure drops. Improves hearing and results of vestibular tests in patients with ENT organs, reduces dizziness and tinnitus. In vascular pathology eye restores the functional activity of the retina.

Indications:
CHD, angina, coronary Commission (in the complex therapy), chorioretinal circulatory disorders, dizziness of vascular origin, dizziness, Meniere's disease with, tinnitus.

Contraindications:
Hypersensitivity, pregnancy, lactation.

Side effects:
Allergic reaction (itching), rarely - weak dyspeptic symptoms (nausea, vomiting, stomachalgia).

Dosage and administration:
Inside, 20 mg 2-3 times a day (40-60 mg / day) during meals.


Description Trimetazid product is not intended for purposes of treatment without the participation of a physician.